Rare Possibility to Fight Cancer Investigated

  • ChemPubSoc Europe Logo
  • Author: Chemistry – A European Journal
  • Published Date: 09 June 2019
  • Source / Publisher: Chemistry – A European Journal/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Rare Possibility to Fight Cancer Investigated

Related Societies

Metabolic and immune disorders are important factors in the formation of tumors. However, only a limited number of studies investigated the possibility to combat cancer through the combination of mitochondria-targeting and immune-modulating properties.


Zong-Wan Mao, Sun Yat-Sen University, Guangzhou, China, and colleagues have developed cyclometalated Ir(III) complexes containing well-known anti-inflammatory agents, such as salicylic acid and aspirin (acetylsalicylic acid). The complexes are [Ir(ppy)2(L)](PF6) (ppy: 2‐phenylpyridine; L: [2,2′‐bipyridine]‐4,4′‐diylbis(methylene) bis(2‐hydroxybenzoate)) and [Ir(ppy)2(L')](PF6) (pictured above, L': [2,2′‐bipyridine]‐4,4′‐diylbis(methylene) bis(2‐acetoxybenzoate)). The ester bonds connecting the metal complex and the salicylic acid derivative are hydrolyzed by esterases in the body (pictured below). 

 

 

The molecular conjugates can induce mitochondrial dysfunction and metabolic disorder. They also regulate the activity of immune factors. The conjugates can inhibit several events related to tumor metastasis and show potent tumor growth inhibition. Due to their strong phosphorescent emission with long lifetimes, the compounds can also be used to track the morphological changes in mitochondria.


According to the researchers, their work shows that targeting mitochondria and cancer immunity can effectively double-hit cancer cells. It also provides suggestions for the development of other metal-based anticancer agents with multiple functionalities.


 

Article Views: 1019

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH